Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
ABEO submitted a Form 144 notice reporting a proposed sale of 112,276 shares of Common Stock tied to Restricted Stock Awards, dated 06/05/2026 with an effective filing date of 06/08/2026.
The filing also reports prior transactions: Vishwas Seshadri sold 29,958 shares on 03/31/2026 with an aggregate reported value of $131,363.00. The filing is an SEC notification of proposed resale under equity compensation rules.
ABEO submitted a Form 144 notice reporting a proposed sale of 25,000 shares of Common Stock through Stifel Nicolaus & Company Inc. The filing also lists 51,747 Restricted Stock Awards and indicates an earlier reported sale of 785 shares for $3,737.00 on 03/16/2026. The transaction dates shown include 06/05/2026 and 06/08/2026.
Abeona Therapeutics reported that it held a pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration regarding ABO-701, its engineered T-cell therapy targeting Prostate-Specific Membrane Antigen for prostate cancer. The company believes the meeting was constructive and is still aiming to submit an IND application for ABO-701 in 2027, in line with its prior timeline. Management notes there is no assurance the FDA will not request additional studies or data, or that any eventual IND submission will be accepted or allow clinical trials to begin, and highlights that development plans may change based on FDA feedback, preclinical results, manufacturing considerations, financing, and other risks described in its SEC filings.
Abeona Therapeutics director Mark Alvino reported a bona fide gift of 500 shares of Common Stock. The gift was recorded at a price of $0.00 per share, reflecting a non-market, no‑consideration transfer. Following this disposition, he directly holds 77,065 shares of Abeona Therapeutics common stock.
Abeona Therapeutics director Mark Alvino reported an open-market sale of company stock. He sold 6,500 shares of common stock on May 22, 2026 at a weighted average price of $5.4558 per share, through multiple trades priced between $5.44 and $5.47.
After this transaction, Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. The filing notes that full details of the individual trade prices within the reported range are available upon request.
Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock on May 15, 2026 at a weighted average price of $5.5325 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on February 4, 2026, indicating the transactions were pre-arranged. Following this sale, Crombez directly holds 37,313 shares of Abeona Therapeutics common stock.
ABEONA THERAPEUTICS INC. Schedule 13G/A amendment reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 5,775,350 shares of common stock as of March 31, 2026. The filing states these holdings represent 9.99% of the outstanding shares for each Reporting Person. The disclosure notes 762,298 shares of the total may be acquired within sixty days through the exercise of convertible securities. Shared voting and dispositive power over the 5,775,350 shares is recorded for Nantahala, Harkey and Mack.
ABEONA THERAPEUTICS INC. reports amended beneficial ownership by Nantahala Capital Partners. As of March 31, 2026, Nantahala may be deemed the beneficial owner of 3,333,757 shares, representing 5.82% of the class based on 57,049,023 shares outstanding as of December 31, 2025. The reported total includes 179,832 shares that may be acquired within sixty days upon exercise of securities. The filing shows shared voting and dispositive power over the full position.